Justin Schreiber Sells 25,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the transaction, the chief executive officer now owns 2,703,715 shares in the company, valued at $14,032,280.85. The trade was a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $5.54 on Wednesday. The firm’s 50 day moving average is $5.56 and its two-hundred day moving average is $5.56. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. The firm has a market capitalization of $239.95 million, a P/E ratio of -8.66 and a beta of 1.49. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $12.88.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. ClariVest Asset Management LLC boosted its stake in shares of LifeMD by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock worth $631,000 after acquiring an additional 2,600 shares in the last quarter. Quest Partners LLC acquired a new position in shares of LifeMD in the 2nd quarter valued at $31,000. Deerfield Management Company L.P. Series C increased its stake in LifeMD by 25.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 40,289 shares of the company’s stock worth $276,000 after purchasing an additional 8,204 shares in the last quarter. nVerses Capital LLC acquired a new stake in LifeMD during the 3rd quarter worth about $46,000. Finally, Intech Investment Management LLC purchased a new stake in LifeMD during the third quarter valued at about $54,000. 35.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LFMD. Lake Street Capital assumed coverage on LifeMD in a report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. Mizuho started coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.57.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.